准分子激光消融联合药物涂层球囊治疗下肢动脉硬化闭塞症的安全性与有效性
本研究评估准分子激光消融(ELA)联合药物涂层球囊(DCB)治疗下肢动脉硬化闭塞症(ASO)的安全性和有效性。共纳入71例患者,主要终点为主要截肢无生存率(MAFS)。技术成功率为93.0%,12个月一期通畅率为92.0%±27.6%,MAFS为96.0%±20.0%。作者认为早期结果显示ELA是治疗原发病变、支架内再狭窄(ISR)和慢性完全闭塞(CTO)病变的有效方法,中期和长期结果有待观察。
要点
- 71例下肢ASO患者接受ELA联合DCB治疗,技术成功率93.0%。
- 12个月一期通畅率92.0%±27.6%,MAFS为96.0%±20.0%。
- 作者认为ELA是治疗原发病变、ISR和CTO病变的有效方法,中期和长期结果有待观察。
核心结论
- 早期结果显示ELA是治疗原发病变、支架内再狭窄(ISR)和慢性完全闭塞(CTO)病变的有效方法。
- ELA可为DCB的使用准备管腔并减少支架植入,尤其是在不适合支架植入的节段。
- 中期和长期结果有待观察。
研究设计与样本
- 2019年6月至2020年12月纳入所有符合条件的患者,收集并分析人口学特征、病变特征、并发症和随访信息。
- 主要终点为主要截肢无生存率(MAFS),次要终点包括技术成功、一期通畅率、补救性支架、远端栓塞、靶病变再干预(TLR)和溃疡愈合率。
- MAFS和一期通畅率采用Kaplan-Meier分析计算,共纳入71例患者。
主要发现
- 48例(81.7%)患者表现为严重肢体缺血(CLI),其中48.6%的患者根据外周动脉钙化评分系统(PACSS)为钙化4级。
- 慢性完全闭塞(CTO)病变最常见,占66.0%;股浅动脉(SFA)是最常见的节段,占59.6%。
- 技术成功率为93.0%,25例(35.2%)患者完成1年随访。
- 12个月时一期通畅率为92.0%±27.6%,MAFS为96.0%±20.0%。
- 在平均9.4±4.3个月的随访期间,临床驱动的TLR发生于2例(2.8%)患者,大截肢和小截肢分别发生于2例(2.8%)和1例(1.4%)患者。
临床怎么用
- 作者认为ELA是治疗原发病变、ISR和CTO病变的有效方法。
- 作者认为ELA可为DCB的使用准备管腔并减少支架植入,尤其是在不适合支架植入的节段。
局限性
- 中期和长期结果有待观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and effectiveness of excimer laser ablation (ELA) combined with drug-coated balloon (DCB) for atherosclerotic obliterans (ASO) of the lower extremities. MATERIALS AND METHODS: From June 2019 to December 2020, all eligible patients were enrolled. Demographics, characteristics of lesions, complications, and follow-up information were collected and analyzed. The primary endpoint was major amputation-free survival (MAFS). Secondary endpoints included technical success, primary patency, bailout stent, distal embolization, target lesion reintervention (TLR), and ulcer healing rate. Major amputation-free survival and primary patency were calculated by Kaplan-Meier analysis. RESULTS: A total of 71 patients were enrolled. Forty-eight (81.7%) patients presented critical limb ischemia (CLI) and 48.6% of them was calcification class 4 according to Peripheral Arterial Calcium Scoring System (PACSS). Chronic totally occluded (CTO) disease was the most common lesion in 66.0% of them and superficial femoral artery (SFA) was the most common segment in 59.6%. Technical success rate was 93.0%. One-year follow-up was finished in 25 (35.2%) patients. The primary patency and MAFS were 92.0%±27.6% and 96.0%±20.0% at 12 months, respectively. During the mean follow-up of 9.4±4.3 months, clinically-driven TLR occurred in 2 (2.8%) patients, and major and minor amputation occurred in 2 (2.8%) and 1 (1.4%) patient, respectively. CONCLUSION: The early results demonstrated that ELA was an effective treatment in de novo, in-stent restenosis (ISR) and CTO lesions. Meanwhile, ELA could prepare the lumen for the use of DCB and reduce the implantation of stents, especially in segments unsuitable for stenting. Mid-term and long-term results need to be awaited.
引用
- Jiang X, Ju S, Chen B, et al. Safety and Effectiveness of Excimer Laser Ablation Combined With Drug-Coated Balloon for Atherosclerotic Obliterans in the Lower Extremity. J Endovasc Ther. 2022. PMID: 35514287. doi:10.1177/15266028221092979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。